Singer Jesy Nelson Breaks Down Over Terrifying Pregnancy Complications- Why Twin-to-Twin Transfusion Syndrome Is So Dangerous?

Updated Mar 7, 2025 | 01:00 AM IST

SummaryTwin-to-twin transfusion syndrome (TTTS) is a rare pregnancy complication in identical twins sharing a placenta, causing uneven blood flow, which can lead to severe health risks or fatal outcomes if untreated.
Singer Jesy Nelson Breaks Down Over Terrifying Pregnancy Complications- Why Twin-to-Twin Transfusion Syndrome Is So Dangerous

Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

  • 90% of the cases of untreated TTTS lead to loss of one or both twins.
  • Despite treatment, only a 70% survival rate for both twins is assured.
  • Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
  • Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

End of Article

'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Updated Nov 17, 2026 | 11:08 AM IST

SummaryDeveloped by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression including memory, thinking, and everyday functioning by the equivalent of 3.5 months over one year.
'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Credit: iStock

A new once-daily experimental pill slowed the decline in memory, thinking, and everyday functioning by 31% in some people with Alzheimer's disease in a Phase 3 trial.

Developed by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression by the equivalent of 3.5 months over one year.

Unlike existing dementia drugs, which primarily alleviate symptoms, AR1001 has shown potential to slow disease progression.

However, the benefit was significant only among patients who were not taking other dementia medications.

The company announced that "the trial had met its primary endpoint" at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, US.

What Did The Phase 3 Trial Find?

Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For

The global trial involved 1,535 people with Alzheimer's disease across 230 sites in 13 countries.

Researchers assessed participants using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, judgment and the ability to perform everyday activities.

The findings showed:

  • 31% slower decline: Among 604 patients taking AR1001 without other dementia medications, disease progression was 31% slower than in the placebo group.
  • 3.5-month delay: The difference was equivalent to delaying disease progression by approximately 3.5 months over one year.
  • No significant benefit in the overall group: Among all 1,535 participants, the benefit was 7% and was not statistically significant.

The findings suggest that AR1001's effectiveness may depend on whether patients are taking other Alzheimer's medications.

Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, described the results as encouraging.

"These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms," Dr Richard said, the Daily Mail reported.

"Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third," he added.

Why Is AR1001 Being Called 'Viagra For The Brain'?

Read More: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

AR1001 works differently from existing Alzheimer's treatments, such as lecanemab and donanemab, which target amyloid plaques in the brain.

Its active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, the compound used in Viagra to treat erectile dysfunction.

Both drugs inhibit an enzyme called phosphodiesterase-5 (PDE5). This helps relax blood vessels and improve blood flow.

Researchers believe AR1001 may have several effects in the brain, including:

  • Improving blood flow.
  • Reducing inflammation.
  • Protecting nerve cells.
  • Supporting cellular processes involved in brain function.

Unlike some existing disease-modifying treatments that require infusions or injections, AR1001 is designed as a once-daily oral medication.

However, the drug is from the same family of medicines as Viagra and is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.

Are there Any Side Effects?

Most side effects reported during the trial were mild to moderate. Common side effects included diarrhoea, falls and dizziness.

Severe adverse events occurred in 10% of the treatment group and 9.8% of the placebo group.

Researchers also reported changes in biomarkers associated with Alzheimer's disease. Levels of the protein p-tau217 decreased in the monotherapy group, while cerebrospinal fluid cGMP levels increased in both treatment groups.

These findings offer clues about the drug's biological activity, although further research is needed to establish its effects.

However, the lack of a statistically significant benefit among people taking other Alzheimer's medications, adding that this required further investigation.

AR1001 is not yet available to the public and must undergo regulatory assessment before it can be prescribed.

Regulatory approval will depend on further evaluation, including whether the FDA considers the monotherapy results sufficient to support the drug's approval.

End of Article

L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Updated Nov 17, 2026 | 09:27 AM IST

SummaryL'Oréal USA and several of its subsidiaries recently settled lawsuits related to their chemical hair relaxers and cancer risk in a trial held in Chicago,
L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Credit: AI-generated image

L'Oréal USA and other manufacturers of chemical hair relaxers have reached a settlement with four women who alleged that years of using hair straightening products contributed to their gynaecological cancers.

The settlement was made during the first US trial involving these claims, bringing newfound attention to research examining the health risks of chemical hair treatments.

What Do We Know About The L'Oréal's US Lawsuit?

According to Reuters, the four women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, settled their lawsuits for an undisclosed amount. The trial was being held in Chicago.

The women had sued L'Oréal's US subsidiary and several other manufacturers in 2023 and 2024, alleging that prolonged exposure to chemical hair straighteners caused their cancers.

The settlement comes as litigation involving these products continues to surface. More than 12,700 related cases have been consolidated before a federal judge in Chicago.

The products, sold under brand names including Dark and Lovely and Optimum, have been widely marketed to Black women.

Also read: What Is Viral Heightmaxxing? US Doctors Warn Teen Boys Against Taking Cancer Drug To Grow Taller

L'Oréal's Statement

L'Oréal has maintained that its products are safe. A company spokesperson said, "L’Oréal USA strictly follows all regulations in every market in which it operates and its products are always subject to a rigorous scientific evaluation of their safety."

The company has also argued that existing research does not establish that its products caused the conditions alleged in the lawsuits.

What Does Research Say About Hair Relaxers And Cancer?

Scientific interest in the health effects of chemical hair straighteners increased after a 2022 study by researchers at the US National Institutes of Health (NIH).

Published in the Journal of the National Cancer Institute, the study examined data from 33,497 women aged 35-74 participating in the Sister Study.

Over an average follow-up of nearly 11 years, 378 cases of uterine cancer were identified.

Researchers found that women who reported using chemical hair straightening products more than four times in the preceding year had more than twice the risk of developing uterine cancer compared to women who had never used them.

The study estimated that 1.64% of women who had never used hair straighteners would develop uterine cancer by age 70, compared to 4.05% among frequent users.

However, researchers did not focus on the specific brands or chemical ingredients used, meaning they could not identify which substances might have contributed to the observed association.

Also read: Can A 'Sponge On A String' Test Help Detect Oesophageal Cancer Before Symptoms?

High Risk Of Breast And Ovarian Cancer

Other studies have also investigated links between chemical hair treatments and reproductive cancers.

A 2021 study published in Carcinogenesis found that frequent use of hair straighteners and relaxers may cause an increased risk of ovarian cancer. Women who used these products more than four times a year had approximately twice the risk compared with non-users.

Research from the Sister Study cohort has also showed an increased risk of breast cancer due to frequent hair straightener use especially among women who used the products regularly.

However, the findings are not the same across all studies. A 2025 systematic review examining evidence among Black women in the US concluded that the epidemiological evidence that is available did not support an increased risk of breast, ovarian or uterine cancers due to hair relaxer use.

Are Chemicals In Hair Straighteners Dangerous For Health?

Chemical hair relaxers and straighteners contain different substances depending on their formulation. Some products may contain endocrine-disrupting chemicals, including phthalates and parabens, which can interfere with hormonal activity.

Other concerning chemicals include formaldehyde and certain preservatives. Some straightening treatments can release formaldehyde, a recognised carcinogen.

Researchers have suggested that exposure to endocrine-disrupting chemicals could affect hormonal tissues.

End of Article

Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Updated Nov 17, 2026 | 08:46 AM IST

SummaryThe European Commission granted marketing authorisation to Revolution Medicines to produce and sell RASONQUE (daraxonrasib) to treat aggressive metastatic pancreatic adenocarcinoma.
Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Credit: AI-generated image

The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.

The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.

RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.

The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.

More About RASONQUE

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.

Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.

Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.

Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.

Also read: Bowel, Pancreatic & Liver: NHS Trial Offers New Blood Test To 20,000 Patients That Could Detect 13 Cancers

What Did The Clinical Trial Find?

The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.

According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.

Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.

The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.

Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients

What Are The Side Effects?

The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.

The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.

Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.

Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.

The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.

End of Article